Dr. Martens (LON:DOCS) Trading Down 12% – Should You Sell?

Shares of Dr. Martens plc (LON:DOCS) fell 12% during mid-day trading on Tuesday . The company traded as low as GBX 64.60 and last traded at GBX 66.55. 2,111,753 shares were traded during trading, an increase of 27% from the average session volume of 1,659,168 shares. The stock had previously closed at GBX 75.65.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DOCS. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Berenberg Bank restated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Stock Down 12.3%

The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The company has a 50 day simple moving average of GBX 76.53 and a two-hundred day simple moving average of GBX 83.47. The company has a market capitalization of £641.31 million, a P/E ratio of 39.03, a PEG ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, equities analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current year.

Insider Buying and Selling at Dr. Martens

In other news, insider Robert Hanson bought 96,000 shares of Dr. Martens stock in a transaction dated Friday, December 5th. The shares were acquired at an average price of GBX 79 per share, with a total value of £75,840. Insiders have acquired a total of 97,130 shares of company stock valued at $7,673,816 over the last quarter. Corporate insiders own 2.79% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.